Previous Article | Next Article ![]()
Infection and Immunity, April 2001, p. 1983-1993, Vol. 69, No. 4
Department of Microbiology and Immunology,
University of Maryland School of Medicine, Baltimore, Maryland 21201
Received 28 June 2000/Returned for modification 2 October
2000/Accepted 18 December 2000
Bordetella pertussis, the causative agent of whooping
cough, regulates expression of many virulence factors via a
two-component signal transduction system encoded by the
bvgAS regulatory locus. It has been shown by transcription
activation kinetics that several of the virulence factors are
differentially regulated. fha is transcribed within 10 min
following a bvgAS-inducing signal, while prn is
transcribed after 1 h and ptx is not transcribed until 2 to 4 h after induction. These genes therefore represent early, intermediate, and late classes of bvg-activated promoters,
respectively. Although there have been many insightful studies into the
mechanisms of BvgAS-mediated regulation, the role that differential
regulation of virulence genes plays in B. pertussis
pathogenicity has not been characterized. We provide evidence that
alterations to the promoter regions of bvg-activated genes
can alter the kinetic pattern of expression of these genes without
changing steady-state transcription levels. In addition, B. pertussis strains containing these promoter alterations that
express either ptx at an early time or fha at a
late time demonstrate a significant reduction in their ability to
colonize respiratory tracts in an intranasal mouse model of
infection. These data suggest a role for differential regulation
of bvg-activated genes, and therefore for the BvgAS regulatory system, in the pathogenicity of B. pertussis.
Bordetella pertussis, the
causative agent of whooping cough, regulates expression of many of its
virulence factors via a two-component signal transduction system
encoded by the bvgAS regulatory locus (3,
35). This system mediates the transition of B. pertussis between a virulent Bvg+ phase and an
avirulent Bvg In a mouse model of B. pertussis infection, several lines of
evidence indicate that the Bvg In contrast, cell culture experiments have indicated that B. pertussis modulates the expression of adenylate cyclase-hemolysin toxin upon cell invasion (22), providing in vitro evidence
of a possible role for bvg regulation in intracellular
survival, although the relevance of this for B. pertussis
pathogenicity is not known. Also, the characterization of a
Bvg-intermediate (Bvgi) phase of B. pertussis
has identified factors specific to this phase. Some of these antigens
are recognized by antibodies in sera from children recovering from
pertussis (21), suggesting that the Bvgi phase
of B. pertussis is expressed in vivo.
Although it has been known for some time that, based on Bvg activation
kinetics, there are both early and late classes of bvg-activated promoters (31), we have recently
identified a third, intermediate class of bvg-activated
promoters, represented by prn (17), a gene that
encodes putative adherence factor pertactin (19). However,
the role that differential regulation of bvg-activated promoters plays in pathogenicity has not been characterized. It has
been hypothesized, based on the kinetic patterns of expression, that
the adhesins are expressed early in order to colonize the respiratory
tract of the host and that the toxins are expressed late when they are
needed to avoid host defenses (26). Thus far, as described
above, there is little or no evidence supporting a role for the
Bvg Bacterial strains and growth conditions.
The bacterial
strains and plasmids used or constructed in this study are described
below. Escherichia coli strains were grown on Luria-Bertani
agar. B. pertussis strains were grown on Bordet-Gengou (BG)
agar (Difco) supplemented with 15% sheep blood or in Stainer-Scholte liquid medium (33). Magnesium sulfate was added to 50 mM
when modulation was required. The following antibiotics were added to
the concentrations indicated (micrograms per milliliter) when necessary: ampicillin, 100; chloramphenicol, 20; tetracycline, 10;
gentamicin, 10; kanamycin, 50; streptomycin, 400; nalidixic acid, 20. Bacterial conjugations were performed as described previously (13) with E. coli S17.1 as the donor strain
(32).
DNA manipulations and allelic exchange.
DNA manipulations
were carried out by standard molecular methods. Constructs were
introduced into the B. pertussis genome by allelic exchange
using pSS1129 (35), a mobilizable suicide vector. B. pertussis strain KMC3, which has the fha genes under the control of the ptx promoter and upstream BvgA-binding
sequence, was constructed as follows. An EcoRV site was
introduced by overlap extension PCR (8) just after the
fha transcription start site (by changing sequence
GATTTC to GATATC at nucleotides 184 to 189 downstream from the EcoRI site) in a subclone of the
fha upstream region. A fragment upstream of the
ptx genes including the promoter and upstream BvgA-binding
sequence (from
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.4.1983-1993.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Differential Regulation of Bvg-Activated Virulence
Factors Plays a Role in Bordetella pertussis
Pathogenicity
and
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
phase. Recently there have been many
insightful studies into the mechanisms of BvgAS-mediated regulation
(5, 6, 7, 17, 20, 34, 37), but a complete picture of the
role that this regulation plays in Bordetella virulence has
remained elusive. It has been speculated that changes in
microenvironments during the course of infection may provide modulating
signals that control virulence gene expression to allow for survival,
persistence, evasion of immune response, and transmission. However, the
small amount of experimental evidence that exists is inconclusive. In a
Bordetella bronchiseptica rabbit model of infection, the
Bvg+ phase was found to be necessary and sufficient for
establishment of respiratory tract infection (11).
Although the Bvg
phase did not appear to contribute to
virulence, it was shown to be advantageous for survival in a
nutrient-deprived environment (11). In addition, a rat
model of B. bronchiseptica infection demonstrated no
evidence of in vivo expression of Bvg
phase factors
(2). Moreover, the ectopic expression of a
Bvg
phase flagellar protein during the Bvg+
phase resulted in reduced tracheal colonization (2).
phase is unnecessary for,
and even detrimental to, virulence. In one study, the Bvg+
phase was also found to be necessary and sufficient for colonization: a
deletion of bvgR (encoding a Bvg-activated repressor of some Bvg
phase genes [24]), resulting in
ectopic expression of Bvg
phase factors, decreased the
efficiency of colonization, and a reporter system designed to determine
in vivo expression indicated that vrg6 (a Bvg
phase gene [18]) expression is low in vivo
(21). An additional strain in which the bvgR
gene was deleted induced levels of leukocytosis that were significantly
lower than those induced by the wild-type strain in an aerosol
challenge of adult mice (23). These data challenge a role
for the Bvg
phase in vivo and establish that a function
of the bvg locus in pathogenicity may be repression of the
bvg-repressed genes.
phase in pathogenicity or the occurrence of
modulation in vivo. We hypothesized that, by making changes to the
promoter regions of bvg-activated genes, we could alter
their kinetic patterns of expression. We further hypothesized that, if
the differential regulation seen in vitro has a role in the virulence
of B. pertussis, changing the regulatory kinetics between
classes of promoters should decrease the virulence of the organism.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
236 to +2 with respect to the transcription start
site) was then amplified by PCR, incorporating an EcoRI site
into the upstream primer and an EcoRV site into the
downstream primer. This fragment was then digested with
EcoRI and EcoRV and ligated into the modified
fha subclone between the EcoRI and
EcoRV sites, thus replacing the fha promoter and
upstream sequence with that of ptx. This construct was then
introduced into B. pertussis Tohama I (15) by
conjugation and allelic exchange and confirmed by PCR.
RT-PCR analysis. Total RNA was prepared from B. pertussis strains by extraction with Trizol LS reagent (Gibco BRL) and then treatment with RNase-free DNase I (Boehringer Mannheim) to remove any contaminating DNA. Two micrograms of total RNA was used in reverse transcriptase (RT) reactions (all components were from Gibco BRL) with SuperScript II RT (200 U) and primed with random hexamers (50 ng) to synthesize first-strand cDNA as described previously (17). Samples without RT were also run to verify the absence of DNA contamination. After treatment with RNase H (Gibco BRL), 10% of the first-strand reaction product was used as the template in subsequent PCRs. RT-PCR mixtures (50 µl) contained 100 pmol of primers, 1× PCR buffer, 1.5 mM MgCl2, 0.4 mM deoxynucleoside triphosphates, and 0.5 µl of Taq DNA polymerase (all components were from Gibco BRL). The prn RT-PCR mixtures also contained 5% dimethyl sulfoxide (Fisher Scientific). The reactions were run for 25 cycles of 1 min at 94°C for denaturing, 1 min at 52°C for annealing (60°C annealing for rpoA primers), and 1.5 min at 72°C for extension in a thermal cycler. The products were electrophoresed on a 2% agarose gel, stained with ethidium bromide, and visualized with UV light.
Time course analyses of bvg-activated transcription. B. pertussis strains Tohama I, KMC3, W28, NMD386, and NMD387 were grown on nitrocellulose filters on BG agar plates containing 50 mM MgSO4 to modulate bvg activity. At time zero, the filters were transferred to medium without MgSO4 to induce bvg activity as described previously (17). Total RNA was prepared as described above from cells at various times after induction, as described in Results. Total RNA was also prepared when B. pertussis strains W28, NMD386, and NMD387 were used to inoculate liquid cultures at time zero after being modulated on BG agar plates containing 50 mM MgSO4. RT-PCR, with primers (forward and reverse, respectively) specific for sodB (5'CTGCCTTACGCTCTGGATG3' and 5'GGACGGGCATTGCGGTAAT3'), fha (5'CCTAAAACGAGCAGGCCG3' and 5'GAACTTGTTGTGCGAGAC3'), and ptx (5'GCACCATCGTCACCG3' and 5'CCTCGTTCGCACCCATGG3'), was used as described above to determine promoter activation (Tohama I and KMC3 time course analyses). The following primer pairs (forward and reverse, respectively) were used for W28, NMD386, and NMD387 time course analyses: rpoA, 5'CCGCACGACGTCGAGATCAT3' and 5'AACACCGAGATCTGGTCCAT3'; ptx, 5'GCCACGTGAGATCCGAGG3' and 5'GTCTATCACAACGGCATC3'; prn, 5'CGACAAATAGCGTGCGTT3' and 5'GGTCGGACGCCTGGATA3'. To analyze the RT-PCR data, portions of the RT-PCR samples were run on an agarose gel and stained with the fluorescent dye Vistra green (Amersham) and band intensities were quantified by analysis on a FluorImager SI system using ImageQuant software (Molecular Dynamics). The band intensities were normalized to the sodB standard, a bvg-independent gene encoding superoxide dismutase of B. pertussis (12), or to the rpoA standard, the bvg-independent gene encoding the alpha subunit of RNA polymerase (9).
Assay for FHA and PT production. To compare the levels of FHA produced by KMC3 to those produced by B. pertussis strains Tohama I and Tohama I fha-lac and of pertussis toxin (PT) secreted by the ptx promoter-altered mutant strains to those secreted by wild-type B. pertussis strain W28, Western immunoblotting of whole-cell lysates or trichloroacetic acid (TCA)-precipitated supernatant proteins, respectively, was used. Three 15-ml liquid cultures per strain were inoculated to the same optical density (OD) from cells grown on plates for 2 days. After 24 h of growth, FHA strains were diluted to an OD at 600 nm (OD600) of 0.5 units/ml and lysed with sample buffer and further diluted for analysis. Filter-sterilized culture supernatants containing secreted PT were precipitated by TCA as described previously (8). The precipitated proteins were resuspended in 1 M Tris-HCL (pH 7)-0.5 N NaOH in volumes normalized to the OD of the cultures at harvest. Sample buffer was added to a series of fivefold dilutions of the precipitated proteins. Samples were run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels (15% polyacrylamide) and transferred to nitrocellulose by Western blotting. FHA was detected with an FHA-specific goat polyclonal antibody, while the S1 subunit was detected with X2X5, an S1-specific monoclonal antibody (4), followed by a peroxidase-conjugated secondary antibody (Boehringer Mannheim) and enhanced chemiluminescence development (Amersham). Densitometric analysis of the developed films with a Bio-Rad GS 700 imaging densitometer allowed the comparison of the levels of proteins produced by the mutant and wild-type strains.
CHO cell clustering assay. One milliliter of each of the above culture supernatants, following filter sterilization but prior to TCA precipitation, was retained to compare the levels of secreted PT with a Chinese hamster ovary (CHO) cell clustering assay (14). The supernatant volumes were normalized for differences in the culture densities and diluted in phosphate-buffered saline (PBS) (Gibco BRL) in a series of fourfold dilutions. One-microliter portions of undiluted supernatant and 1:4, 1:16, and 1:64 dilutions of supernatants were added to 24-well plates with 5 × 104 CHO cells per well. The plates were incubated for 2 days, stained with Giemsa stain (Sigma Diagnostics), and scored for clustering of CHO cells.
Experimental animals and inoculation procedure.
Six- to
8-week-old, female, BALB/c mice (Charles River Laboratories) were used
in this study. Inocula were prepared by growing B. pertussis
strains at 37°C on BG-blood agar with streptomycin for 3 days, after
which the strains were passed onto new plates and grown for two
additional days. The harvested cells were then resuspended in sterile
PBS plus 1% Casamino Acids (PBS-CAA). Mice were inoculated
intranasally with 20 µl of PBS-CAA containing approximately 5 × 104 CFU, unless otherwise noted, while the animals were
lightly anesthetized with Metofane (Mallinckrodt Veterinary). For the
experiments involving the addition of PT to the bacterial inoculum,
wild-type and mutant (PT9K/129G [25]) toxins were
purified from B. pertussis culture supernatants by the
fetuin affinity method of Kimura et al. (16) and the PT B
oligomer was from CalBiochem. The inocula were diluted and plated on
BG-blood agar with streptomycin and viable counts were determined in
order to normalize between inoculated groups of mice. At various times
postinoculation, mice were sacrificed by carbon dioxide inhalation and
the trachea and lungs were removed, homogenized in 2 ml of PBS-CAA,
diluted, and plated on BG-blood agar with streptomycin. Four to 5 days
later the plates were counted and the number of CFU per respiratory
tract was determined. Statistical significance was determined by
Student's t test of the normalized data, the natural
logarithms of the normalized data, and the ranking of the natural
logarithms of the normalized data. Strains were considered
significantly altered when P was
0.05 by all three t tests. The P values shown are from the
t tests of the natural logarithms of the normalized data.
| |
RESULTS |
|---|
|
|
|---|
Construction and characterization of an fha promoter
replacement strain.
Although it is believed that the promoter
regions of bvg-activated genes are responsible for the
differential regulation of these genes, there is no direct in vivo
evidence of this. We constructed a strain, KMC3, in which the upstream
region from the early bvg-activated fha gene,
including the promoter and BvgA-binding sequences (5), was
replaced by the equivalent region from upstream of the late bvg-activated ptx gene (20) by
allelic exchange (Fig. 1A). This placed
fha under the control of the ptx promoter.
Previous studies have determined that fha is expressed early
following an inducing signal, while ptx is expressed late
(17, 31). We used RT-PCR, as previously described
(17), to analyze the activation kinetics of strain KMC3.
Total RNA was prepared from cells at 0, 60, 120, 240, and 480 min. In
strain KMC3, fha was expressed late, similar to
ptx expression (Fig. 1B) and different from the
early-induction kinetics of fha in wild-type strain Tohama I
that we previously demonstrated (17). This result confirms
the anticipated switch in promoter control compared to that for
wild-type strain Tohama I, in which fha was expressed by 30 min (17). It also provides direct evidence that the
promoter region is responsible for the differential regulation seen in
vitro.
|
Effect of fha promoter exchange on colonization
of the mouse respiratory tract.
In an initial attempt to
determine the effect of fha-to-ptx promoter
exchange on the virulence of B. pertussis, we used an intranasal mouse model of infection and examined the ability of the
mutant strain to colonize the respiratory tracts of mice. Mice were
inoculated intranasally with approximately 5 × 104
CFU of wild-type strain Tohama I or mutant strain KMC3 in 20 µl of
PBS-CAA. After 7 days, the mice were sacrificed and the trachea and
lungs were removed, homogenized, diluted, and plated to determine
levels of colonization. Mice inoculated with late-expressing fha strain KMC3 had a statistically significant 86%
reduction (approximately 1 log unit) (P = 0.032) in
mean respiratory tract colonization compared to mice inoculated with
wild-type strain Tohama I (Fig. 2).
|
strain of B. pertussis) to determine the effect of our promoter alteration.
Cultures were grown in triplicate and were diluted to an
OD600 of 0.5. Twentyfold dilutions were analyzed by Western blotting. FHA was detected with an FHA-specific goat polyclonal antibody (obtained from Rino Rappuoli) (Fig.
3); densitometric analysis demonstrated
that there was not a significant difference (P = 0.8)
between levels of FHA produced by KMC3 and Tohama I. In addition, to
determine that there was no effect of the presence of a duplicate copy
of the ptx promoter on the production of PT in strain KMC3,
we used a CHO cell clustering assay (14) and compared the
levels of active PT secreted by KMC3 and Tohama I. Dilutions of
supernatants (undiluted and 1:4, 1:16, and 1:64 dilutions) from
triplicate cultures were assayed. There were no significant differences
in clustering patterns induced by the supernatants of the wild-type and
fha promoter mutant strains, indicating that there is no
defect in PT production in KMC3. These data suggest that the altered
expression of fha is responsible for the colonization defect
of KMC3 in the intranasal mouse model of infection (Fig. 2).
|
Construction and analysis of activation kinetics of ptx
promoter mutants.
We have provided evidence that alteration of the
kinetic pattern of fha expression from early to late is
detrimental for optimal colonization and thus for full virulence.
However, attempts to create the reciprocal strain, in which the
late-activated ptx promoter is replaced by the
early-activated fha promoter, resulted in a slowly growing
strain that was not suitable for further study. As an alternative
approach, we determined whether two strains with previously
characterized ptx promoter alterations (20) were altered in their ptx activation kinetic patterns. These
strains had retained promoter activities close to that of the wild type despite the ptx promoter modifications (20).
NMD346 had a deletion of 65 bp in the intervening sequence, while
NMD357 had a replacement of the ptx BvgA-binding heptameric
inverted repeats with those of fha, but the native 10-bp
sequence between the inverted repeats was maintained. These promoter
alterations fused to the wild-type ptx open reading frame
sequence (instead of lac) were introduced into the
chromosome of B. pertussis strain W28 by allelic exchange to
generate NMD386 and NMD387, respectively (Fig.
4A), the appropriate construction of
which was confirmed by PCR.
|
Effect of ptx promoter alterations on level of secreted
PT.
To compare the levels of active PT secreted by the strains
with ptx promoter alterations with those secreted by
wild-type B. pertussis W28, we used the CHO cell clustering
assay described above. There were no significant differences in the
overall patterns of clustering as a function of the supernatant PT
concentrations of W28, NMD386, and NMD387 (Fig.
5A). This provides semiquantitative evidence that the cytotoxic activity and the levels of PT secreted by
these ptx promoter mutant strains are the same as those for wild-type strain W28.
|
Effect of ptx promoter alterations on colonization of
the mouse respiratory tract.
In order to determine the effect of
the altered ptx activation kinetics on the virulence of
B. pertussis, we used the intranasal mouse model of
infection to examine the abilities of the mutant strains to colonize
the respiratory tracts of mice. Eight or nine mice per group were
inoculated with approximately 5 × 104 CFU in 20 µl
of PBS-CAA on day 0. On day 8, the mice were sacrificed and the trachea
and lungs were removed, homogenized, diluted, and plated. Four to 5 days later colonies were counted and the CFU per respiratory tract were
normalized to the initial inoculum level as determined by the viable
counts of the inoculum (Fig. 6). Both
mutant strains demonstrated a significant reduction in the ability to
colonize the respiratory tracts of mice compared to wild-type strain
W28. There was a 92% reduction (approximately 1 log unit) in the mean
CFU per respiratory tract between W28 and NMD386 (P = 0.0004) and a 64% reduction (approximately 1/2 log unit) between
W28 and NMD387 (P = 0.010) (Fig. 6). The extent of the
defect in colonization correlated with the extent of alteration of
promoter activation kinetics (NMD386 had the earliest ptx
activation). These data indicate that the altered expression of
ptx has an inhibitory effect on the ability of B. pertussis to colonize the respiratory tracts of mice. This
suggests a role for differential regulation of bvg-activated
genes in pathogenicity.
|
|
|
Effect of addition of PT to B. pertussis inoculum on
colonization.
The above data indicate that the altered expression
of ptx has a negative effect on the ability of B. pertussis to colonize the respiratory tracts of intranasally
infected mice. A recent report indicated that when a human bronchial
epithelial cell line was preincubated with increasing concentrations of
purified PT, washed, and then incubated with B. pertussis
strains, there was a dose-dependent reduction of adherence of the
bacteria to the bronchial cells (38). These data provide
evidence that PT can inhibit the adherence of B. pertussis
to epithelial cells, which led us to the hypothesis that the virulence
defect demonstrated by the ptx promoter mutants could be an
effect of the altered expression of ptx resulting in
inhibition of initial bacterial adherence to the respiratory tract by
PT. To test this hypothesis, we determined whether the addition of
purified PT to the inoculum of wild-type B. pertussis might
mimic the virulence defect of the ptx promoter mutants,
NMD386 and NMD387, by interfering with initial adherence. We therefore
inoculated mice with 5 × 104 CFU of B. pertussis W28 resuspended in buffer alone or with 1 or 10 µg of
purified PT added. After 7 days, the mice were sacrificed and the
trachea and lungs were removed, homogenized, diluted, and plated.
Surprisingly, the addition of 1 and 10 µg of purified wild-type PT
resulted in statistically significant 7-fold (not shown) and 10-fold
(Fig. 9) increases, respectively, in the
level of B. pertussis colonization of the respiratory tracts
of the infected mice.
|
Role of modulation in colonization.
In order for the early
expression of ptx to have an effect on the virulence of
B. pertussis, we hypothesized that, at some point
during the course of infection, down-regulation or modulation of
ptx expression would be required. Using RT-PCR analysis, as described previously, we investigated whether the time of preparation of the bacterial inoculum (approximately 45 min to 1 h at
room temperature in our standard protocol) was enough to down-regulate the expression of ptx. B. pertussis W28 cells
were resuspended in PBS-CAA and maintained either at room
temperature or at 37°C for 1 h, after which total RNA was
isolated from both sets of cells for RT-PCR analysis with primers
specific for bvg-independent gene rpoA and for
ptx. The experiment was repeated three times, and the RT-PCR
results are shown in Fig. 10A. The room
temperature and 37°C ptx products were run on an agarose
gel, stained with Vistra green, and normalized to the rpoA
standard. An average 84% reduction in expression between the 37°C
and room temperature ptx products was observed. This
indicates that room temperature, a known modulator of the BvgAS system,
is able to down-regulate expression of ptx within 1 h,
the average time between removal of B. pertussis cells from
the 37°C incubator for preparation of inocula and intranasal
inoculation of mice.
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study we have provided evidence that alterations to the promoter regions of bvg-activated genes can alter the kinetic patterns of expression of these genes. In addition, B. pertussis strains containing these promoter alterations demonstrate a reduction in the ability to colonize respiratory tracts in an intranasal mouse model of infection, i.e., a virulence defect. In particular, the altered regulation of the characteristically early-activated fha promoter and that of the characteristically late-activated ptx promoter both result in approximately a 1-log-unit reduction in the numbers of bacteria colonizing the respiratory tracts of mice. These data suggest a role for differential regulation of bvg-activated genes, and therefore for the BvgAS regulatory system, in the virulence of B. pertussis.
Changes as substantial as the replacement of the entire fha promoter region with the ptx promoter region, as well as more-subtle changes such as the deletion of 65 bp of the intervening-sequence region and the alteration of 4 bp in the heptameric inverted-repeat sequence in the ptx promoter region, resulted in altered kinetic patterns of expression of fha and ptx, respectively. This provides further evidence that the promoter regions of bvg-activated genes are responsible for the differential regulation seen in vitro. The early expression of ptx in NMD386, the strain with the deletion of the 65-bp intervening-sequence region, further supports the cooperative binding model of activation by BvgA at the ptx promoter put forth by Boucher and Stibitz (6). In this model, supported by biochemical and genetic data, phosphorylated BvgA binds first to a site which includes the heptameric inverted repeats. Subsequent cooperative binding of BvgA dimers along the intervening sequence between the initial binding site and the promoter allows BvgA to interact with RNA polymerase to promote transcription activation (6, 20). Although DNase I footprinting analysis will have to be performed to confirm this, we expect from the altered kinetic pattern that this mutant no longer requires the extensive cooperative binding, and thus the high concentration of BvgA, that is needed for activation at the wild-type ptx promoter and is therefore activated earlier (at lower BvgA concentrations) after an inducing signal. The intermediate kinetics of ptx in NMD387, in which the ptx heptameric inverted repeats are replaced by the fha inverted repeats, suggests that higher-affinity binding of BvgA to the primary binding sites of bvg-activated promoters also results in faster transcriptional activation. We believe that the altered activation kinetics of these strains supports the hypothesis that a combination of the affinity of BvgA for the primary binding site and the distance between this site and the core promoter sequences at bvg-activated promoters is primarily responsible for the differential regulation of bvg-activated genes. By using variations in the bvg-activating regions of genes in the Bvg regulon, B. pertussis appears to have optimized its virulence or colonization abilities through differential regulation of at least some of its virulence genes using the products of its two-component signal transduction system.
The above data suggest a mechanism for B. pertussis to be
able to respond to subtle changes in the environment and control the
expression of its positively regulated virulence factors accordingly. However, a role for differential regulation in the pathogenicity of Bordetella remains elusive. The Bvg+ phase is
necessary and sufficient for colonization of animal respiratory tracts
(11, 21), while the Bvg
phase appears not to
have a role in virulence and may even be detrimental (2, 21,
23). These data suggest that there is no role for the
Bvg
phase in vivo and that one function of the
bvg locus in pathogenicity is repression of the
bvg-repressed genes. However, there is some indication that
the Bvgi phase of B. pertussis is expressed in
vivo (21). We believed that if regulation by the BvgAS
system is important for pathogenicity, changing the regulatory circuit
between classes of bvg-activated promoters should affect
virulence. We hypothesized that, by making changes to the promoter
regions of bvg-activated genes, we could alter their
patterns of regulation, manifested as a change in activation kinetics.
Furthermore, we hypothesized that, if the differential regulation
characterized in vitro has a role in the pathogenicity of
B. pertussis, exchanging the regulatory control between
classes of promoters should decrease the virulence of the organism.
Our analysis of B. pertussis mutants altered in their kinetic patterns of expression of fha and ptx indicates that the altered regulation of bvg-activated virulence factors reduces colonization of the mouse respiratory tract. In particular, ptx promoter mutants NMD386 and NMD387 demonstrate a statistically significant reduction in the ability to colonize the respiratory tracts of intranasally infected mice. Our data indicate that this colonization defect is dose dependent and that the pattern of reduced colonization is apparent throughout the course of a 12-day infection. Although the reduction of colonization is not statistically significant at the 2-day time point, the pattern of reduced colonization appears to be already established. Our data strongly suggest that the colonization defect of NMD386 and NMD387 is an effect of the altered regulation of ptx expression in these strains, as there are no significant differences in the steady-state levels of transcriptional activity or expression of PT between the ptx promoter mutant strains and wild-type strain W28. The colonization defect demonstrated by KMC3, the fha-to-ptx promoter replacement strain, also appears to be an effect of the altered regulation of fha expression.
We contend that, at some point prior to or during the course of infection, at least partial modulation of Bvg activity in B. pertussis would have to occur in order for the altered regulatory control in our mutants to have a deleterious effect. This could occur either in the respiratory tract of the host or prior to encounter with the host. It is possible that modulation occurs throughout the course of infection as the organism is exposed to different microenvironments in the host's respiratory tract. The immune response to the recently identified Bvgi phase factors provides evidence to support this (21). Our data indicate that 1 h at room temperature is sufficient to reduce ptx transcription by an average of 84%. However, our results also indicate that the maintenance of the wild-type B. pertussis inoculum at 37°C, thus inhibiting the ability of the Bvg system to modulate its virulence factors prior to inoculation, does not significantly affect the ability of the organism to colonize the respiratory tracts of intranasally infected mice. It remains possible that differential regulation is required during the course of infection within the host for optimal virulence of B. pertussis rather than prior to encounter with the host. Characterization of differential expression of bvg-activated genes throughout the course of infection would have to be examined to address this. Furthermore, we cannot rule out a role for differential regulation in the course of transmission between infected individuals during which B. pertussis may remain aerosolized for considerable periods of time (1). It is possible that an effect of the preinoculation modulation may be more dramatic at either an earlier or later harvest time point. Use of the aerosol challenge mouse model may also offer further insight into the role of differential regulation in transmission as it may provide a more relevant model of exposure to the organism and the early stages of infection. It is possible that the virulence defects of our regulatory mutants may be magnified using this model.
A recent study by van den Berg et al. (38) provided a possible explanation as to why the early presence of PT might have an inhibitory effect on the ability of B. pertussis to colonize the respiratory tracts of mice. This report indicated that, despite previous accounts that PT has a role as an adherence factor (36), PT does not augment B. pertussis adherence to cultured human cells and, in fact, can even inhibit B. pertussis adherence in vitro (38). However, we did not detect a dose-dependent inhibitory effect of added purified PT in our intranasal mouse model of infection to support this as a possible reason for the reduced ability of our ptx promoter mutants to colonize. It is possible that the addition of lower concentrations of the purified toxins or B oligomer may have demonstrated an inhibitory effect without enhancing bacterial virulence (presumably by overwhelming the immune system of the mice). However, the artificial addition of PT to the inoculum is probably quite different from B. pertussis production of PT and the local concentrations of bacteria and toxins present in a natural infection.
One can speculate that the complexity of an organism's regulatory mechanisms may correlate with the complexity of the bacterium's life cycle. It is possible that the adaptability afforded to B. pertussis by its complex regulatory components and phosphotransfer steps enables the bacterium to respond to a series of changing microenvironments throughout the course of infection. We demonstrate that B. pertussis utilizes differences in the promoters of its bvg-activated virulence factors to allow for differential expression of these genes using only the BvgAS system. Furthermore, we provide evidence that this differential regulation is required for optimal virulence. We believe that the temporal expression demonstrated in vitro likely reflects the sensitivity of a particular bvg-activated promoter to modulatory signals. This is consistent with the requirement for higher concentrations of transcriptional activator BvgA at the late-acting promoters (31). In further support of this idea, we have recently found that the intermediately activated prn promoter (17) is most transcriptionally active at intermediate levels of modulator MgSO4 (S. M. Kinnear and N. H. Carbonetti, unpublished data).
Two possible hypotheses may explain the role of differential regulation of bvg-activated genes during the course of infection. The first is that temporal regulation of virulence gene expression is important for colonization and the resulting infection. Incorporating our data, a possible model to explain the role of temporal regulation of bvg-activated virulence factors is as follows. Following a coughing paroxysm of a pertussis patient, the aerosolized organisms are exposed to the lower temperature of the environment and the BvgAS system is thereby modulated or down-regulated. As the aerosol droplet reaches the nasal passages of the next host, the least-sensitive fha promoter is either still on or is immediately activated and the intermediately sensitive prn promoter is transcribed at its highest level to facilitate the ability of FHA to colonize the respiratory tract. It has been proposed that pertactin (PRN) acts as an accessory adherence factor, perhaps in conjunction with FHA. PRN may be important as a scaffolding or support component of an adhesin complex (27, 28, 29). Our data indicate that, if there is some modulation of the BvgAS system in the time between aerosolization of the organism and transmission to the next host, prn expression would be at its peak. At the same time, the most sensitive ptx promoter is turned off so as not to have an inhibitory effect on initial adherence.
An alternative hypothesis is that differential regulation of bvg-activated virulence gene expression occurs in response to spatial rather than temporal cues. This hypothesis suggests that in vivo microenvironments differ in their modulatory signals. Some microenvironments may present cues that are perceived as semimodulating and thus would induce expression of adhesins (such as FHA and PRN) but repress toxin expression. Other microenvironments may be nonmodulating and thus would induce expression of both adhesins and toxins. From previous data (21, 23), it seems unlikely that there are fully modulating in vivo microenvironments that would inhibit the expression of the bvg-activated factors and induce the expression of the bvg-repressed factors. According to this hypothesis of spatial cues, virulence genes would be differentially regulated depending on the location of the bacteria within the host respiratory tract to result in optimal infection. The two hypotheses are not necessarily mutually exclusive, since the location of bacteria within a host may be dependent to some extent on the time after the first encounter with the host.
An additional, more trivial possibility is that the differences in
colonization levels between the wild-type and mutant strains are due to
differences in the steady-state expression levels of FHA and PT rather
than differences in regulatory control. However densitometric analysis
of Western blots and cytotoxicity assays for PT activity indicated that
there were no significant differences in the levels of FHA and PT
expressed between the strains in vitro (Fig. 3 and 5, respectively).
While it may seem surprising that merely altering the regulatory
pattern of expression of FHA should have a measurable effect on
virulence when it has been demonstrated that FHA
mutants
were not affected in virulence in a mouse model (39), the
steady-state lack of a virulence factor is different than an alteration
of regulatory patterns, as in our mutants. The permanent lack of FHA
may be compensated for by an alternative adherence factor in the animal
model, whereas altered regulation of FHA may result in inappropriate
temporal or spatial expression and interference with optimal
bacterium-host interactions for infection. Although we cannot rule out
a possible difference in expression levels in vivo, we believe this to
be an unlikely cause of the virulence defect in our mutant strains and
therefore favor either the temporal or spatial hypotheses presented.
The ability of the BvgAS system to be sensitive to small changes in
environmental signals via the complexity of its phosphorelay together
with differences in the promoter regions of genes in its regulon may
allow B. pertussis to respond to the intricacy of its life
cycle through the efficiency of one regulatory system.
| |
ACKNOWLEDGMENTS |
|---|
We thank Kyle McKenna for the construction of KMC3; Monica Castro and Uli McNamara for technical assistance; Abdu Azad and Suzana Radulovic for mice; Abdu Azad, Drusilla Burns, and Rino Rappuoli for reagents; Alla Romashko and the University of Maryland Animal Facility for assistance with mouse experiments; and Colin O'Connell for help with figures. We also thank Steve Wasserman for advice on statistics and Jim Kaper and Jim Nataro for critical reading of the manuscript. We are also grateful to both anonymous reviewers, whose painstakingly thorough critiques of the manuscript helped to improve it significantly.
This work was supported by NIH grants AI32946 and AI38979.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: University of Maryland School of Medicine, Department of Microbiology and Immunology, BRB 13-009, 655 W. Baltimore St., Baltimore, MD 21201-1559. Phone: (410) 706-7677. Fax: (410) 706-2129. E-mail: ncarbone{at}umaryland.edu.
Present address: Center for Vaccine Development, University of
Maryland School of Medicine, Baltimore, MD 21201.
Editor: V. J. DiRita
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Aintablian, N., P. Walpita, and M. H. Sawyer. 1998. Detection of Bordetella pertussis and respiratory syncytial virus in air samples from hospital rooms. Infect. Control Hosp. Epidemiol. 19:918-923[Medline]. |
| 2. | Akerley, B. J., P. A. Cotter, and J. F. Miller. 1995. Ectopic expression of the flagellar regulon alters development of the Bordetella-host interaction. Cell 80:611-620[CrossRef][Medline]. |
| 3. |
Arico, B.,
J. F. Miller,
C. R. Roy,
S. Stibitz,
D. Monack,
S. Falkow,
R. Gross, and R. Rappuoli.
1989.
Sequences required for expression of Bordetella pertussis virulence factors share homology with prokaryotic signal transduction proteins.
Proc. Natl. Acad. Sci. USA
86:6671-6675 |
| 4. | Bartoloni, A., M. Pizza, M. Bigio, D. Nucci, L. A. Ashworth, L. I. Irons, A. Robinson, D. Burns, C. Manclark, H. Sato, and R. Rappuoli. 1988. Binding of a protective epitope of pertussis toxin by in vitro refolding of recombinant fragments. Bio/Technology 6:709-712[CrossRef]. |
| 5. |
Boucher, P. E.,
K. Murakami,
A. Ishihama, and S. Stibitz.
1997.
Nature of DNA binding and RNA polymerase interaction of the Bordetella pertussis BvgA transcriptional activator at the fha promoter.
J. Bacteriol.
179:1755-1763 |
| 6. |
Boucher, P. E., and S. Stibitz.
1995.
Synergistic binding of RNA polymerase and BvgA phosphate to the pertussis toxin promoter of Bordetella pertussis.
J. Bacteriol.
177:6486-6491 |
| 7. | Boucher, P. E., F. D. Menozzi, and C. Locht. 1994. The modular architecture of bacterial response regulators: insights into the activation mechanism of the BvgA transactivator of Bordetella pertussis. J. Mol. Biol. 241:363-377[CrossRef][Medline]. |
| 8. |
Carbonetti, N. H.,
T. J. Irish,
C. H. Chen,
C. B. O'Connell,
G. A. Hadley,
U. McNamara,
R. G. Tuskan, and G. K. Lewis.
1999.
Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway.
Infect. Immun.
67:602-607 |
| 9. |
Carbonetti, N. H.,
T. M. Fuchs,
A. A. Patamawenu,
T. J. Irish,
H. Deppisch, and R. Gross.
1994.
Effect of mutations causing overexpression of RNA polymerase subunit on regulation of virulence factors in Bordetella pertussis.
J. Bacteriol.
176:7267-7273 |
| 10. | Cotter, P. A., and J. F. Miller. 1997. A mutation in the Bordetella bronchiseptica bvgS gene results in reduced virulence and increased resistance to starvation, and identifies a new class of Bvg-regulated antigens. Mol. Microbiol. 24:671-685[CrossRef][Medline]. |
| 11. |
Cotter, P. A., and J. F. Miller.
1994.
BvgAS-mediated signal transduction: analysis of phase-locked regulatory mutants of Bordetella bronchiseptica in a rabbit model.
Infect. Immun.
62:3381-3390 |
| 12. | DeShazer, D., J. D. Bannan, M. J. Moran, and R. L. Friedman. 1994. Characterization of the gene encoding superoxide dismutase of Bordetella pertussis and construction of a SOD-deficient mutant. Gene 142:85-89[CrossRef][Medline]. |
| 13. |
Gross, R., and R. Rappuoli.
1988.
Positive regulation of pertussis toxin expression.
Proc. Natl. Acad. Sci. USA
85:3913-3917 |
| 14. |
Hewlett, E. L.,
K. T. Sauer,
G. A. Meyers,
J. L. Cowell, and R. L. Guerrant.
1983.
Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin.
Infect. Immun.
40:1198-1230 |
| 15. | Kasuga, T., Y. Nakase, K. Ukishima, and K. Takatsu. 1954. Studies on Haemophilus pertussis. Relation between the phase of bacilli and the progress of the whooping cough. Kitasato Arch. Exp. Med. 27:57-62[Medline]. |
| 16. |
Kimura, A.,
K. T. Mountzouros,
D. A. Relman,
S. Falkow, and J. L. Cowell.
1990.
Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model.
Infect. Immun.
58:7-16 |
| 17. |
Kinnear, S. M.,
P. E. Boucher,
S. Stibitz, and N. H. Carbonetti.
1999.
Analysis of BvgA activation of the pertactin gene promoter in Bordetella pertussis.
J. Bacteriol.
181:5234-5241 |
| 18. |
Knapp, S., and J. Mekalanos.
1988.
Two trans-acting regulatory genes (vir and mod) control antigenic modulation in Bordetella pertussis.
J. Bacteriol.
170:5059-5066 |
| 19. |
Leininger, E.,
M. Roberts,
J. G. Kenimer,
I. G. Charles,
N. Fairweather,
P. Novotny, and M. J. Brennan.
1991.
Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence to mammalian cells.
Proc. Natl. Acad. Sci. USA
88:345-349 |
| 20. | Marques, R. R., and N. H. Carbonetti. 1997. Genetic analysis of pertussis toxin promoter activation in Bordetella pertussis. Mol. Microbiol. 24:1215-1224[CrossRef][Medline]. |
| 21. |
Martinez de Tejeda, G.,
P. A. Cotter,
U. Heininger,
A. Camilli,
B. J. Akerley,
J. J. Mekalanos, and J. F. Miller.
1998.
Neither the Bvg phase nor the vrg6 locus of Bordetella pertussis is required for respiratory infection in mice.
Infect. Immun.
66:2762-2768 |
| 22. |
Masure, H. R.
1992.
Modulation of adenylate cyclase toxin production as Bordetella pertussis enters human macrophages.
Proc. Natl. Acad. Sci. USA
89:6521-6525 |
| 23. |
Merkel, T. J.,
S. Stibitz,
J. M. Keith,
M. Leef, and R. Shahin.
1998.
Contribution of regulation by the bvg locus to respiratory infection of mice by Bordetella pertussis.
Infect. Immun.
66:4367-4373 |
| 24. |
Merkel, T. J., and S. Stibitz.
1995.
Identification of a locus required for the regulation of bvg-repressed genes in Bordetella pertussis.
J. Bacteriol.
177:2727-2736 |
| 25. |
Pizza, M.,
A. Covacci,
A. Bartoloni,
M. Perugini,
L. Nencioni,
M. T. DeMagistris,
L. Villa,
D. Nucci,
R. Manetti,
M. Bugnoli,
F. Giovannoni,
R. Olivieri,
J. T. Barbieri,
H. Sato, and R. Rappuoli.
1989.
Mutants of pertussis toxin suitable for vaccine development.
Science
246:497-500 |
| 26. | Rappuoli, R., B. Arico, and V. Scarlato. 1992. Thermoregulation and reversible differentiation in Bordetella: a model for pathogenic bacteria. Mol. Microbiol. 6:2209-2211[CrossRef][Medline]. |
| 27. | Relman, D. A., and S. Falkow. 1994. A molecular perspective of microbial pathogenicity, p. 19-29. In G. L. Mandell, R. E. Douglas, and E. Bennett (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, New York, N.Y. |
| 28. | Relman, D. A. 1995. Bordetella pertussis: determinants of virulence, p. 367-405. In J. Moss, B. Iglewski, M. Vaughn, and A. T. Tu (ed.), Bacterial toxins and virulence factors in disease. M. Dekker, New York, N.Y. 367-405. |
| 29. | Roberts, M., N. F. Fairweather, E. Leininger, D. Pickard, E. L. Hewlett, A. Robinson, C. Hayward, G. Dougan, and I. G. Charles. 1991. Construction and characterization of Bordetella pertussis mutants lacking the vir-regulated P.69 outer membrane protein. Mol. Microbiol. 5:1393-1404[CrossRef][Medline]. |
| 30. | Robinson, A. L., A. E. Ashworth, A. Baskerville, and L. I. Irons. 1985. Proceedings of the 4th International Symposium on Pertussis. Dev. Biol. Stand. 61:165-172[Medline]. |
| 31. |
Scarlato, V.,
A. Prugnola,
B. Arico, and R. Rappuoli.
1990.
Positive transcriptional feedback at the bvg locus controls expression of virulence factors in Bordetella pertussis.
Proc. Natl. Acad. Sci. USA
87:6753-6757 |
| 32. | Simon, R., U. Priefer, and A. Pühler. 1983. A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in gram negative bacteria. Bio/Technology 1:784-791[CrossRef]. |
| 33. |
Stainer, D. W., and M. J. Scholte.
1970.
A simple chemically defined medium for the production of phase I Bordetella pertussis.
J. Gen. Microbiol.
63:211-220 |
| 34. | Steffen, P., S. Goyard, and A. Ullmann. 1996. Phosphorylated BvgA is sufficient for transcriptional activation of virulence-regulated genes in Bordetella pertussis. EMBO J. 15:102-109[Medline]. |
| 35. |
Stibitz, S., and M.-S. Yang.
1991.
Subcellular location and immunological detection of proteins encoded by the vir locus of Bordetella pertussis.
J. Bacteriol.
173:4288-4296 |
| 36. | Tuomanen, E., and A. Weiss. 1985. Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells. J. Infect. Dis. 152:118-125[Medline]. |
| 37. | Uhl, M. A., and J. F. Miller. 1996. Integration of multiple domains in a two-component sensor protein: the Bordetella pertussis BvgAS phosphorelay. EMBO J. 15:1028-1036[Medline]. |
| 38. |
van den Berg, B. M.,
H. Beekhuzuizen,
R. J. L. Willems,
F. R. Mooi, and R. van Furth.
1999.
Role of Bordetella pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tracts.
Infect. Immun.
67:1056-1062 |
| 39. |
Weiss, A. A., and M. S. Goodwin.
1989.
Lethal infection by Bordetella pertussis mutants in the infant mouse model.
Infect. Immun.
57:3757-3764 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»